SPAST and primary progressive multiple sclerosis: The lack of a pronounced increase in sGFAP levels in PPMS compared to SPG4 might be attributed to the small sample size (25/25 subjects), as the difference between PPMS patients and controls (25/60 subjects) who had sGFAP levels similar to SPG4 was significant.